Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 830
Summary
- Conditions
- Mild Cognitive Impairment
- Prodromal Alzheimer's Disease
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 55 years and 85 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03486938
- Collaborators
- National Institute on Aging (NIA)
- Investigators
- Principal Investigator: Richard Mohs, PhD AgeneBio Study Director: Sharon Rosenzweig-Lipson, PhD AgeneBio Study Director: Russell Barton, MS AgeneBio
Get Well Soon